@FierceBiotech: FDA delays review of key Takeda diabetes drug and Actos combo. Item | Follow @FierceBiotech
@MaureenFierce: Sad: U.S. seniors having to pay more for their Rx drugs, according to a new study. Story | Follow @MaureenFierce
@MarkHFierce: So Russia plans to be a global device competitor by 2020? Hmmm... Release | Follow @MarkHFierce
> Allocure has revealed some upbeat data from a Phase I study of its stem-cell therapy for acute kidney injury. Article
> The FDA has given Tonix Pharmaceuticals ($TNXP) the green light to go forward with trials of its drug TNX-102 for treating fibromyalgia. Release
> Chelsea Therapeutics ($CHTP) has garnered a priority review for its experimental hypertension drug Northera. Report
> Former AstraZeneca employees in the U.K. whose jobs were axed by the drug giant have set up their own life sciences shops. Item
> Alnylam Pharmaceuticals ($ALNY) has granted a non-exclusive license to its RNA-interference platform to Spanish biotech Sylentis to work on a synthetic siRNA drug for treating glaucoma. Release
> Eli Lilly ($LLY) has awarded a $4.2 million grant to the Infectious Disease Research Institute in Seattle to fund early work on hunting for drugs against tuberculosis. Article
Pharma News
@FiercePharma: Counterfeiting tricks emerge in Chinese crackdown. E.g., to make fake little blue pills blue, add printer ink. News | Follow@FiercePharma
> Sandoz settles pricing suits with Florida, California. Report
> Eisai to hawk Novartis meds, while Shionogi sells for Shire. Article
> Pfizer, J&J among lawmakers' fave drug stocks. Item
> FDA pulls Avastin's breast cancer approval. Report
> EU watchdogs: Pradaxa risk can be managed. News
> Pfizer exec: Indian price move would push pharma to 'semi-recession.' Report
And Finally... Do you want to load up on tryptophan on Thanksgiving? You'll find more of it in roasted chicken than turkey. Item